|Rescreening of persons with a negative colonoscopy result: results from a microsimulation model.|
|PMID: 23128861 Owner: NLM Status: MEDLINE|
|BACKGROUND: Persons with a negative result on screening colonoscopy are recommended to repeat the procedure in 10 years.
OBJECTIVE: To assess the effectiveness and costs of colonoscopy versus other rescreening strategies after an initial negative colonoscopy result.
DESIGN: Microsimulation model.
DATA SOURCES: Literature and data from the Surveillance, Epidemiology, and End Results program.
TARGET POPULATION: Persons aged 50 years who had no adenomas or cancer detected on screening colonoscopy.
TIME HORIZON: Lifetime.
INTERVENTION: No further screening or rescreening starting at age 60 years with colonoscopy every 10 years, annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immunochemical testing (FIT), or computed tomographic colonography (CTC) every 5 years.
OUTCOME MEASURES: Lifetime cases of colorectal cancer, life expectancy, and lifetime costs per 1000 persons, assuming either perfect or imperfect adherence.
RESULTS OF BASE-CASE ANALYSIS: Rescreening with any method substantially reduced the risk for colorectal cancer compared with no further screening (range, 7.7 to 12.6 lifetime cases per 1000 persons [perfect adherence] and 17.7 to 20.9 lifetime cases per 1000 persons [imperfect adherence] vs. 31.3 lifetime cases per 1000 persons with no further screening). In both adherence scenarios, the differences in life-years across rescreening strategies were small (range, 30 893 to 30 902 life-years per 1000 persons [perfect adherence] vs. 30 865 to 30 869 life-years per 1000 persons [imperfect adherence]). Rescreening with HSFOBT, FIT, or CTC had fewer complications and was less costly than continuing colonoscopy.
RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to test-specific adherence rates.
LIMITATION: Data on adherence to rescreening were limited.
CONCLUSION: Compared with the currently recommended strategy of continuing colonoscopy every 10 years after an initial negative examination, rescreening at age 60 years with annual HSFOBT, annual FIT, or CTC every 5 years provides approximately the same benefit in life-years with fewer complications at a lower cost. Therefore, it is reasonable to use other methods to rescreen persons with negative colonoscopy results.
PRIMARY FUNDING SOURCE: National Cancer Institute.
|Amy B Knudsen; Chin Hur; G Scott Gazelle; Deborah Schrag; Elizabeth G McFarland; Karen M Kuntz|
|Type: Journal Article; Research Support, N.I.H., Extramural|
|Title: Annals of internal medicine Volume: 157 ISSN: 1539-3704 ISO Abbreviation: Ann. Intern. Med. Publication Date: 2012 Nov|
|Created Date: 2012-11-06 Completed Date: 2013-04-08 Revised Date: 2013-05-20|
Medline Journal Info:
|Nlm Unique ID: 0372351 Medline TA: Ann Intern Med Country: United States|
|Languages: eng Pagination: 611-20 Citation Subset: AIM; IM|
|Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, 10th Floor, Boston, MA 02114, USA. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
prevention & control
Colonography, Computed Tomographic / adverse effects, economics
Colonoscopy / adverse effects, economics*
Colorectal Neoplasms / prevention & control*
Early Detection of Cancer / adverse effects, economics*, methods*
Health Care Costs
Immunologic Tests / economics
Mass Screening / adverse effects, economics*, methods*
Sensitivity and Specificity
|RC1 CA147256/CA/NCI NIH HHS; RC1CA147256/CA/NCI NIH HHS; U01 CA088204/CA/NCI NIH HHS; U01 CA152959/CA/NCI NIH HHS; U01CA088204/CA/NCI NIH HHS; U01CA152959/CA/NCI NIH HHS|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type...
Next Document: Two Rotavirus Outbreaks Caused by Genotype G2P at Large Retirement Communities: Cohort Studies.